fah hospital policy blog

Perspectives on health policy affecting America’s hospitals and the patients we serve.

ICYMI: Rep. Cartwright Focuses on Hospitals at Drug Price Hearing

February 11, 2016 | FAH Hospital Policy Blog Team

Category: FAH News, Pharmaceuticals

People are still talking about the fireworks at last week’s House hearing examining the price of prescription drugs. The outspoken former CEO of Turing Pharmaceuticals, 32-year-old Martin Shkreli, grabbed headlines when he pleaded the 5th and walked out of the proceedings early. There were, however, some substantive moments when members from both parties asked tough questions to government officials and drug company leaders.

Read More »

Bipartisan Group of Lawmakers Stands Up for Seniors Against Medicare Cuts

February 10, 2016 | FAH Hospital Policy Blog Team

Category: Backstop, FAH News, Medicare

The entire bipartisan South Florida Congressional delegation signed a letter this week urging the Administration to abandon a budget proposal that would hurt low-income seniors by cutting a critical Medicare provision.

Read More »

FAH on President’s FY17 Budget: Proposed Funding Cuts are “Warmed Over,” Weaken Patient Access

February 09, 2016 | Chip Kahn

Category: FAH News, General, Medicaid, Medicare, Sequester

President Obama’s FY17 budget misses the mark. It does offer hope for sustaining and expanding coverage gains. And it lifts the Medicare sequestration - but nullifies any benefit by replacing it with warmed over cuts that would threaten patient access to hospital care for low income Americans and seniors.

Read More »

Drug Price Hearing Should Focus on Effects of Surging Costs on Community Hospitals

February 03, 2016 | FAH Hospital Policy Blog Team

Category: FAH News, Pharmaceuticals

Thursday morning, the House Committee on Oversight and Government Reform will hold a hearing entitled, “Developments in the Prescription Drug Market.” Members will discuss the reasons for the recent rapid rise in drug prices and the generic drug approval process, while hearing from a wide array of witnesses, including current and former drug company leaders and government officials.

Read More »